GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (OTCPK:RDTCF) » Definitions » 3-Month Share Buyback Ratio

RDTCF (Rapid Dose Therapeutics) 3-Month Share Buyback Ratio : -3.05% (As of Nov. 2024 )


View and export this data going back to 2019. Start your Free Trial

What is Rapid Dose Therapeutics 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Rapid Dose Therapeutics's current 3-Month Share Buyback Ratio was -3.05%.


Competitive Comparison of Rapid Dose Therapeutics's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, Rapid Dose Therapeutics's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's 3-Month Share Buyback Ratio falls into.


;
;

Rapid Dose Therapeutics 3-Month Share Buyback Ratio Calculation

Rapid Dose Therapeutics's 3-Month Share Buyback Ratio for the quarter that ended in Nov. 2024 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Aug. 2024 ) - Shares Outstanding (EOP) (Nov. 2024 )) / Shares Outstanding (EOP) (Aug. 2024 )
=(124.636 - 128.442) / 124.636
=-3.05%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rapid Dose Therapeutics  (OTCPK:RDTCF) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Rapid Dose Therapeutics 3-Month Share Buyback Ratio Related Terms


Rapid Dose Therapeutics Business Description

Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Rapid Dose Therapeutics Headlines

From GuruFocus

Rapid Dose Therapeutics Provides Bi-Weekly MCTO Status Update

By Business Wire Business Wire 07-28-2022

Rapid Dose Announces Board of Director Changes

By Business Wire Business Wire 04-14-2023

Rapid Dose Announces Change of Auditor

By Business Wire Business Wire 05-17-2023

Rapid Dose Announces Filing of Corrective Disclosure

By Business Wire Business Wire 04-14-2023

Rapid Dose Therapeutics Reports Fiscal Year 2022 Financial Results

By Business Wire Business Wire 02-01-2023

Rapid Dose Announces Revocation of Cease Trade Order

By Business Wire Business Wire 05-02-2023